Form 4 for IDXX Idexx Laboratories
Accepted 2021-11-10 00:00:00 ET · period of report 2021-11-08 · accession 0001567619-21-019740 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-10 | 2021-11-08+ | IDXX | MCKEON BRIAN P | CFO, Executive VP | M - OptEx | $67.85 | +16.3K | 32.6K | +100% | +$1.11M |
| DM | 2021-11-10 | 2021-11-08+ | IDXX | MCKEON BRIAN P | CFO, Executive VP | S - Sale+OE | $629.05 | -16.3K | 28.1K | -37% | -$10.26M |
| DM | 2021-11-10 | 2021-11-08+ | IDXX | MCKEON BRIAN P | CFO, Executive VP | M - OptEx | — | -16.3K | 29.2K | -36% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-08 | M | A | 10,000 | $67.85 | 36,316.64 | D | — | — | (F1) Includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021. |
| 2 | Common | Common Stock | 2021-11-08 | S | D | 1,300 | $625.25 | 35,016.64 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $625.00 to $625.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2021-11-08 | S | D | 1,100 | $626.47 | 33,916.64 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $626.10 to $627.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2021-11-08 | S | D | 1,326 | $627.41 | 32,590.64 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $627.07 to $628.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2021-11-08 | S | D | 2,356 | $628.19 | 30,234.64 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $628.01 to $628.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2021-11-09 | S | D | 607 | $631.01 | 26,316.64 | D | — | — | (F11) This transaction was executed in multiple trades at prices ranging from $631.005 to $631.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2021-11-08 | S | D | 971 | $630.39 | 27,169.64 | D | — | — | (F7) This transaction was executed in multiple trades at prices ranging from $630.03 to $630.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 8 | Common | Common Stock | 2021-11-08 | S | D | 743 | $631.39 | 26,426.64 | D | — | — | (F8) This transaction was executed in multiple trades at prices ranging from $631.10 to $631.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Common | Common Stock | 2021-11-08 | S | D | 110 | $632.19 | 26,316.64 | D | — | — | (F9) This transaction was executed in multiple trades at prices ranging from $632.01 to $632.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 10 | Common | Common Stock | 2021-11-09 | M | A | 6,310 | $67.85 | 32,626.64 | D | — | — | |
| 11 | Common | Common Stock | 2021-11-09 | S | D | 5,703 | $630.13 | 26,923.64 | D | — | — | (F10) This transaction was executed in multiple trades at prices ranging from $630.00 to $631.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 12 | Common | Common Stock | 2021-11-08 | S | D | 2,094 | $629.63 | 28,140.64 | D | — | — | (F6) This transaction was executed in multiple trades at prices ranging from $629.10 to $629.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 13 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2021-11-08 | M | D | 10,000 | — | 35,535 | D | $67.85 · — to 2026-02-13 | 10,000 Common Stock | (F13) Not applicable. (F12) Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. |
| 14 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2021-11-09 | M | D | 6,310 | — | 29,225 | D | $67.85 · — to 2026-02-13 | 6,310 Common Stock | (F13) Not applicable. (F12) Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017. |